Cognito Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cognito Therapeutics, Inc. - overview
Established
2016
Location
Cambridge, MA, US
Primary Industry
Medical Devices & Equipment
About
Based in the US, Cognito Therapeutics, Inc. , a. k. a.
Cognito Therapeutics, operates as a developer of a headset to treat neurodegenerative diseases and improve human cognitive performance. Based in Massachusetts, US, and founded in 2016 by co-founders Ed Boyden and Li-Huei Tsai, Cognito Therapeutics, Inc. , a. k.
a. Cognito Therapeutics operates as a developer of disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. In March 2026, Cognito Therapeutics, Inc. raised USD 105 million in series C funding from Morningside, IAG Capital Partners, Starbloom Capital, Vintage Partners, Apollo Health Ventures and Benvolio Group.
Cognito Therapeutics provides an investigational therapeutic platform that delivers non-invasive neuromodulation by using sensory stimulation to evoke gamma oscillations in the brain with personalized treatments, adjustable fit, and self-administered features. The company's platform treats a range of neurodegenerative diseases, including Alzheimer’s disease, and is personalized based on the brain’s responses. Cognito Therapeutics generates revenue by commercializing physician‑prescribed, non‑invasive neurostimulation devices for Alzheimer’s and neurodegenerative diseases, earning income through device sales, clinical partnerships, and future reimbursement‑based distribution following regulatory approvals and market launch. The company plans to use the March 2026 funding to support pivotal study data readout, prepare for FDA submission, advance clinical development of Spectris, and ready the product for commercialization in Alzheimer’s disease.
Current Investors
FoundersX Ventures, WS Investments, Alzheimer's Drug Discovery Foundation
Primary Industry
Medical Devices & Equipment
Sub Industries
Mental Health Services, Therapeutic Devices
Website
www.cognitotx.com
Verticals
Big Data, HealthTech, Manufacturing, Wearables & Quantified Self
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.